Table 1.
Summary of all randomized control trials evaluating the effectiveness and safety of adjuvant amniotic membrane transplantation (AMT) for infectious keratitis.
| Authors | Year | Protocol registration* | Age, years | Male gender | Total eyes (AMT) | Total eyes (control) | Causative organisms (in AMT group) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| B | F | A | V | M | |||||||
| Arya et al.21 | 2008 | N | Mean = 41.8 (AMT) versus 50.8 (control) | 33 (83%) | 20 | 20 | 5 | 12 | 0 | 0 | 3 |
| Li et al.33 | 2014 | N | Mean = 43.8 (AMT) versus 47.0 (control) | 36 (72%) | 25 | 25 | 0 | 25 | 0 | 0 | 0 |
| Tabatabaei et al.20 | 2017 | N | Mean = 48.3 (AMT) vs. 43.4 (control) | 46 (46%) | 49 | 50 | 49 | 0 | 0 | 0 | 0 |
| Zeng et al.22 | 2014 | N | Mean = 57.1 (AMT) vs. 54.0 (control) | 14 (70%) | 10 | 10 | 0 | 10 | 0 | 0 | 0 |
| Authors | Baseline vision (LogMAR) | Time from first presentation to AMT | AMT technique | Severity of ulcer$ | Follow-up (months) | COI | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Arya et al.21 | < 20/400 = 80% (AMT) versus 65% (control) | NR | Overlay (single layer) | 2–5 mm = 60% (AMT) versus 45% (control) | 3 | N | |||||
| Li et al.33 | < 20/200 = 44% (AMT) versus 48% (control) | 2 days | Overlay (single or double layer) | NS | 1 | N | |||||
| Tabatabaei et al.20 | Mean = 1.7 (AMT) versus 1.8 (control) | 2–5 days | Inlay (double layer) | Mean = 26 mm2 (AMT) versus 27 mm2 (control) | 6 | N | |||||
| Zeng et al.22 | Median = 1.0 (AMT) versus 1.0 (control) | NR | Overlay (single layer) | Mean = 7 mm (AMT) versus 7 mm (control) | 1 | N | |||||
B bacteria; F fungi, A acanthamoeba, V viruses, M mixed infection, COI conflict of interest, NR Not reported.
*Prospective registration of the clinical trial protocol in a publicly accessible database.
$Severity of the corneal ulcer is presented either in maximum linear diameter (mm) or in area (mm2).